Skip to main content

Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial.

Publication ,  Journal Article
Singla, N; Warltier, DC; Gandhi, SD; Lumb, PD; Sladen, RN; Aronson, S; Newman, MF; Corwin, HL; ESCAPE-2 Study Group
Published in: Anesth Analg
July 2008

BACKGROUND: Acute postoperative hypertension is a well-known complication of cardiac surgery and is associated with postoperative morbidity. Clevidipine, an ultrashort-acting, third-generation dihydropyridine calcium channel blocker, exerts vascular-selective, arterial-specific vasodilation to decrease arterial blood pressure without negatively impacting cardiac function. In this double-blind, placebo-controlled trial, we examined the efficacy and safety of clevidipine in treating postoperative hypertension in cardiac surgery patients. METHODS: Two hundred six patients undergoing cardiac surgery were randomized preoperatively. Of these, 110 met postrandomization inclusion criteria for the study [systolic blood pressure (SBP) >or=140 mm Hg within 4 h of admission to a postoperative setting, and clinically assessed as needing SBP reduction by >or=15% from baseline]. Patients received an infusion of either clevidipine (0.4-8.0 microg kg(-1) min(-1)) or 20% lipid emulsion (placebo) for 30 min to a maximum of 1 h unless treatment failure occurred sooner. The primary end point was the incidence of treatment failure, defined as the inability to decrease SBP by >or=15% from baseline, or the discontinuation of study treatment for any reason within the 30-min period after study drug initiation. RESULTS: Clevidipine-treated patients had a significantly lower incidence of treatment failure than placebo patients [8.2% (5 of 61) vs 79.6% (39 of 49), P < 0.0001]. Treatment success was achieved in 91.8% of clevidipine-treated patients. Median time to target SBP with clevidipine was 5.3 min (95% confidence interval, 4-7 min). No clinically significant increase in heart rate from baseline was observed. Adverse event rates were similar for both treatment groups. CONCLUSIONS: Clevidipine is effective and safe in the rapid treatment of acute postoperative hypertension after cardiac surgery.

Duke Scholars

Published In

Anesth Analg

DOI

EISSN

1526-7598

Publication Date

July 2008

Volume

107

Issue

1

Start / End Page

59 / 67

Location

United States

Related Subject Headings

  • Treatment Failure
  • Pyridines
  • Prospective Studies
  • Postoperative Complications
  • Middle Aged
  • Male
  • Hypertension
  • Humans
  • Female
  • Double-Blind Method
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Singla, N., Warltier, D. C., Gandhi, S. D., Lumb, P. D., Sladen, R. N., Aronson, S., … ESCAPE-2 Study Group. (2008). Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial. Anesth Analg, 107(1), 59–67. https://doi.org/10.1213/ane.0b013e3181732e53
Singla, Neil, David C. Warltier, Sweeta D. Gandhi, Philip D. Lumb, Robert N. Sladen, Solomon Aronson, Mark F. Newman, Howard L. Corwin, and ESCAPE-2 Study Group. “Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial.Anesth Analg 107, no. 1 (July 2008): 59–67. https://doi.org/10.1213/ane.0b013e3181732e53.

Published In

Anesth Analg

DOI

EISSN

1526-7598

Publication Date

July 2008

Volume

107

Issue

1

Start / End Page

59 / 67

Location

United States

Related Subject Headings

  • Treatment Failure
  • Pyridines
  • Prospective Studies
  • Postoperative Complications
  • Middle Aged
  • Male
  • Hypertension
  • Humans
  • Female
  • Double-Blind Method